Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years

被引：0
|
作者：
X Baraliakos
J Brandt
J Listing
J Sieper
J Braun
机构：
[1] Rheumatology Medical Center Ruhrgebiet,
[2] German Rheumatism Research Center,undefined
[3] University Medicine Berlin,undefined
来源：
Arthritis Research & Therapy | / 7卷
关键词：
Infliximab; Ankylose Spondylitis; Open Label Extension; Infliximab Treatment; Relevant Side Effect;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
    Barallakos, X.
    Brandt, J.
    Listing, J.
    Sieper, J.
    Braun, J.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) : S14 - S14
  • [2] Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Baraliakos, X.
    Listing, J.
    Brandt, J.
    Rudwaleit, M.
    Sieper, J.
    Braun, J.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) : S14 - S14
  • [3] Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    X Baraliakos
    J Listing
    J Brandt
    M Rudwaleit
    J Sieper
    J Braun
    Arthritis Research & Therapy, 7
  • [4] Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
    X Baraliakos
    J Listing
    M Rudwaleit
    J Brandt
    J Sieper
    J Braun
    Arthritis Research & Therapy, 7
  • [5] Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
    Baraliakos, X.
    Listing, J.
    Rudwaleit, M.
    Brandt, J.
    Sieper, J.
    Braun, J.
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 1) : S14 - S14
  • [6] Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years
    Braun, J
    Baraliakos, X
    Brandt, J
    Listing, J
    Zink, A
    Alten, R
    Burmester, G
    Gromnica-Ihle, E
    Kellner, H
    Schneider, M
    Sörensen, H
    Zeidler, H
    Sieper, J
    RHEUMATOLOGY, 2005, 44 (05) : 670 - 676
  • [7] Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing Spondylitis
    Lee, Jeong-Won
    Kang, Ji-Hyoun
    Yim, Yi-Rang
    Kim, Ji-Eun
    Wen, Lihui
    Lee, Kyung-Eun
    Park, Dong-Jin
    Kim, Tae-Jong
    Park, Yong-Wook
    Lee, Shin-Seok
    PLOS ONE, 2015, 10 (07):
  • [8] Adverse Events of Anti-Tumor Necrosis Factor α Therapy in Ankylosing Spondylitis
    Tong, Qiang
    Cai, Qing
    de Mooij, Tristan
    Xu, Xia
    Dai, Shengming
    Qu, Wenchun
    Zhao, Dongbao
    PLOS ONE, 2015, 10 (03):
  • [9] Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis
    Kwon, Inbeom
    Choi, Nayeon
    Shin, Ji Hui
    Lee, Seunghun
    Nam, Bora
    Kim, Tae-Hwan
    JOURNAL OF RHEUMATIC DISEASES, 2024, 31 (01): : 41 - 48
  • [10] Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
    Xenofon Baraliakos
    Joachim Listing
    Jan Brandt
    Martin Rudwaleit
    Joachim Sieper
    Juergen Braun
    Arthritis Research & Therapy, 7
12345